Literature DB >> 12101420

The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.

Mitsuo Sato1, Yoshitsugu Horio, Yoshitaka Sekido, John D Minna, Kaoru Shimokata, Yoshinori Hasegawa.   

Abstract

Promoter hypermethylation is an important means for the transcriptional repression of a number of cancer-associated genes. However, the underlying mechanism of this aberration in cancer remains unclear. Here, we examined 5' CpG island methylation status and expression of the p14(ARF), p16(INK4a) and RASSF1A tumor suppressor genes, and investigated the relationship of these factors with the mRNA expression of DNA methyltransferases (DNMTs) and/or methyl-CpG-binding proteins (MBPs) in 30 lung cancer cell lines including 12 small cell lung cancers (SCLCs) and 18 non-small cell lung cancers (NSCLCs). When beta-actin was used as an internal control, the mRNA expression of three DNMTs (DNMT1, DNMT3A, and DNMT3B) and five MBPs (MBD1, MBD2, MBD3, MBD4, and MeCP2) was upregulated in SCLC, while only that of DNMT1, DNMT3B and MBD3 was upregulated in NSCLC, compared with normal lung tissues. However, when normalized using proliferating cell nuclear antigen (PCNA) as an internal control, these differences disappeared or diminished; there was even a significant reduction in the expression ratios of DNMT1, MBD2 and MeCP2 in SCLC and DNMT1, MBD2 and MBD4 in NSCLC. Furthermore, although significant correlations between PCNA expression and mRNA expression levels of the three DNMTs and four of the MBPs (excluding MeCP2) were observed, there was no obvious correlation between promoter hypermethylation of these tumor suppressor genes and the expression level of any of the DNMTs or MBPs. Our results suggest that upregulation of DNMTs and MBPs probably reflects an increased cell proliferation in human lung cancers and that there are likely to exist gene-specific mechanisms for epigenetic gene silencing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12101420     DOI: 10.1038/sj.onc.1205581

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  Epigenetic aberrant methylation of tumor suppressor genes in small cell lung cancer.

Authors:  Shuai Wang; Zhou Wang
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

2.  Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis.

Authors:  Yan Y Sanders; Annie Pardo; Moisés Selman; Gerard J Nuovo; Trygve O Tollefsbol; Gene P Siegal; James S Hagood
Journal:  Am J Respir Cell Mol Biol       Date:  2008-06-12       Impact factor: 6.914

3.  SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters its activities.

Authors:  Lirong Peng; Zhigang Yuan; Hongbo Ling; Kenji Fukasawa; Keith Robertson; Nancy Olashaw; John Koomen; Jiandong Chen; William S Lane; Edward Seto
Journal:  Mol Cell Biol       Date:  2011-09-26       Impact factor: 4.272

4.  Reduced mRNA expression levels of MBD2 and MBD3 in gastric carcinogenesis.

Authors:  Thaís Brilhante Pontes; Elizabeth Suchi Chen; Carolina Oliveira Gigek; Danielle Queiroz Calcagno; Fernanda Wisnieski; Mariana Ferreira Leal; Samia Demachki; Paulo Pimentel Assumpção; Ricardo Artigiani; Laércio Gomes Lourenço; Rommel Rodriguez Burbano; Marília Arruda Cardoso Smith
Journal:  Tumour Biol       Date:  2013-12-13

5.  Identification of the methylation of p14ARF promoter as a novel non-invasive biomarker for early detection of lung cancer.

Authors:  L Li; Y Shen; M Wang; D Tang; Y Luo; W Jiao; Z Wang; R Yang; K Tian
Journal:  Clin Transl Oncol       Date:  2013-10-24       Impact factor: 3.405

6.  Chromosome 16q genes CDH1, CDH13 and ADAMTS18 are correlated and frequently methylated in human lymphoma.

Authors:  Lobna Alkebsi; Hiroshi Handa; Akihiko Yokohama; Takayuki Saitoh; Norifumi Tsukamoto; Hirokazu Murakami
Journal:  Oncol Lett       Date:  2016-09-09       Impact factor: 2.967

7.  Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer.

Authors:  Brandon J Metge; Andra R Frost; Judy A King; Donna Lynn Dyess; Danny R Welch; Rajeev S Samant; Lalita A Shevde
Journal:  Clin Exp Metastasis       Date:  2008-06-20       Impact factor: 5.150

8.  Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy.

Authors:  Mingqing Tang; William Xu; Qizhao Wang; Weidong Xiao; Ruian Xu
Journal:  Curr Genomics       Date:  2009-08       Impact factor: 2.236

9.  Overexpression of DNA methyltransferase 1 and its biological significance in primary hepatocellular carcinoma.

Authors:  Hong Fan; Zhu-Jiang Zhao; Jian Cheng; Xian-Wei Su; Qing-Xiang Wu; Yun-Feng Shan
Journal:  World J Gastroenterol       Date:  2009-04-28       Impact factor: 5.742

Review 10.  Breast cancer epigenetics: from DNA methylation to microRNAs.

Authors:  Jürgen Veeck; Manel Esteller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-01-27       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.